AbbVie’s Rinvoq and Pfizer’s Cibinqo have been approved to treat moderate-to-severe atopic dermatitis, or eczema, in patients who do not respond to previous treatment or when use of other treatments is not recommended.
Rinvoq’s approval was expanded from rheumatoid arthritis to treat eczema for patients 12 years and older, while Cibinqo was approved for use in only adults.Report ad
Both the drugs belong to a class called JAK inhibitors, which block inflammation-causing enzymes known as Janus kinases and target a range of autoimmune diseases.
Both Pfizer and AbbVie cited risks of serious infections and cardiovascular events, among others.
The expanded approval for Rinvoq follows significant delays amid concerns over safety of JAK inhibitors.
Cibinqo had last year received approvals from the European and UK regulators.
The initial results from a trial showed an increased risk of serious heart-related problems and cancer in some patients being treated with the drug.